A Radiosensitivity Gene Signature and PD-L1 Status Predict Clinical Outcome of Patients with Glioblastoma Multiforme in The Cancer Genome Atlas Dataset
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Combination of radiotherapy and immune checkpoint blockade such as programmed death- 1 (PD-1) or programmed death-ligand 1 (PD-L1) blockade is being actively tested in clinical trial. We aimed to identify a subset of patients that could potentially benefit from this strategy using The Cancer Genome Atlas (TCGA) dataset for glioblastoma (GBM). Materials and Methods A total of 399 cases were clustered into radiosensitive versus radioresistant (RR) groups based on a radiosensitivity gene signature and were also stratified as PD-L1 high versus PD-L1 low groups by expression of CD274 mRNA. Differential and integrated analyses with expression and methylation data were performed. CIBERSORT was used to enumerate the immune repertoire that resulted from transcriptome profiles. Results We identified a subset of GBM, PD-L1-high-RR group which showed worse survival compared to others. In PD-L1-high-RR, differentially expressed genes (DEG) were highly enriched for immune response and mapped into activation of phosphoinositide 3-kinase–AKT and mitogen-activated protein kinase (MAPK) signaling pathways. Integration of DEG and differentially methylated region identified that the kinase MAP3K8-involved in T-cell receptor signaling was upregulated and BAI1, a factor which inhibits angiogenesis, was silenced. CIBERSORT showed that a higher infiltration of the immune repertoire, which included M2 macrophages and regulatory T cells. Conclusion Taken together, PD-L1-high-RR group could potentially benefit from radiotherapy combined with PD-1/PD-L1 blockade and angiogenesis inhibition.
Abstract
Purpose Combination of radiotherapy and immune checkpoint blockade such as programmed death- 1 (PD-1) or programmed death-ligand 1 (PD-L1) blockade is being actively tested in clinical trial. We aimed to identify a subset of patients that could potentially benefit from this strategy using The Cancer Genome Atlas (TCGA) dataset for glioblastoma (GBM). Materials and Methods A total of 399 cases were clustered into radiosensitive versus radioresistant (RR) groups based on a radiosensitivity gene signature and were also stratified as PD-L1 high versus PD-L1 low groups by expression of CD274 mRNA. Differential and integrated analyses with expression and methylation data were performed. CIBERSORT was used to enumerate the immune repertoire that resulted from transcriptome profiles. Results We identified a subset of GBM, PD-L1-high-RR group which showed worse survival compared to others. In PD-L1-high-RR, differentially expressed genes (DEG) were highly enriched for immune response and mapped into activation of phosphoinositide 3-kinase–AKT and mitogen-activated protein kinase (MAPK) signaling pathways. Integration of DEG and differentially methylated region identified that the kinase MAP3K8-involved in T-cell receptor signaling was upregulated and BAI1, a factor which inhibits angiogenesis, was silenced. CIBERSORT showed that a higher infiltration of the immune repertoire, which included M2 macrophages and regulatory T cells. Conclusion Taken together, PD-L1-high-RR group could potentially benefit from radiotherapy combined with PD-1/PD-L1 blockade and angiogenesis inhibition.
참고문헌 (30)
- Ostrom QT, "CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009-2013", Neuro Oncol., 18(Suppl 5), pp.v1~v75 (2016)
- Crane CA, "Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells : implications for immunotherapy", Neuro Oncol, 14, pp.584~595 (2012)
- Huang Y, "Vascular normalization as an emerging strategy to enhance cancer immunotherapy", Cancer Res, 73, pp.2943~2948 (2013)
- Nduom EK, "PD-L1 expression and prognostic impact in glioblastoma", Neuro Oncol, 18, pp.195~205 (2016)
- Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
- Grossman SA, "Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide", Clin Cancer Res, 17, pp.5473~5480 (2011)
- Weichselbaum RR, "Radiotherapy and immunotherapy: a beneficial liaison?", Nat Rev Clin Oncol, 14, pp.365~379 (2017)
- Kim HS, "Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells", BMC Genomics, 13, pp.348~ (2012)
- Ceccarelli M, "Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma", Cell, 164, pp.550~563 (2016)
- Colaprico A, "TCGAbiolinks : an R", Bioconductor package for integrative analysis of TCGA data, 2016, pp.44, e71~
- Jang BS, "A radiosensitivity gene signature and PD-L1status predict clinical outcome of patients with invasive breast carcinoma in The Cancer Genome Atlas(TCGA)dataset", Radiother Oncol, 124, pp.403~410 (2017)
- Webb JR, "PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer", Gynecol Oncol, 141, pp.293~302 (2016)
- Newman AM, "Robust enumeration of cell subsets from tissue expression profiles", Nat Methods, 12, pp.453~457 (2015)
- Finotello F, "Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNAseq data", Genome Med, 11, pp.34~ (2019)
- Cancer Genome Atlas Research Network, "Comprehensive genomic characterization defines human glioblastoma genes and core pathways", Nature, 455, pp.1061~1068 (2008)
- Yoshihara K, "Inferring tumour purity and stromal and immune cell admixture from expression data", Nat Commun, 4, pp.2612~ (2013)
- Wang Z, "Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma", Oncoimmunology, 5, pp.e1196310~ (2016)
- Szulzewsky F, "Investigating the properties of glioma-associated microglia", macrophages, Free University of Berlin Institute of Pharmacy, 2015
- Doucette T, "Immune heterogeneity of glioblastoma subtypes : extrapolation from the cancer genome atlas", Cancer Immunol Res, 1, pp.112~122 (2013)
- Iglesia MD, "Genomic analysis of immune cell infiltrates across 11tumor types", J Natl Cancer Inst, 108, pp.djw144~ (2016)
- Martinez R, "The DNA methylome of glioblastoma multiforme", Neurobiol Dis, 39, pp.40~46 (2010)
- Ruano Y, "Identification of survival-related genes of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma multiforme", Cancer, 112, pp.1575~1584 (2008)
- Zhu D, "Overexpression of MBD2 in glioblastoma maintains epigenetic silencing and inhibits the antiangiogenic function of the tumor suppressor gene BAI1", Cancer Res, 71, pp.5859~5870 (2011)
- Wei J, "Hypoxia potentiates glioma-mediated immunosuppression", PLoS One, 6, pp.e16195~ (2011)
- Platten M, "Concepts for immunotherapies in gliomas", Semin Neurol, 38, pp.62~72 (2018)
- Wang W, "Expression of brain-specific angiogenesis inhibitor 1 is inversely correlated with pathological grade, angiogenesis and peritumoral brain edema in human astrocytomas", Oncol Lett, 5, pp.1513~1518 (2013)
- Hendry SA, "The role of the tumor vasculature in the host immune response : implications for therapeutic strategies targeting the tumor microenvironment", Front Immunol, 7, pp.621~ (2016)
- Ramjiawan RR, "Anti-angiogenesis for cancer revisited : is there a role for combinations with immunotherapy", Angiogenesis, 20, pp.185~204 (2017)
- Zeng J, "Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas", Int J Radiat Oncol Biol Phys, 86, pp.343~349 (2013)
- Sahebjam S, "Atim-18. A phase I trial of hypofractionated stereotactic irradiation (hfsrt) with pembrolizumab and bevacizumab in patients with recurrent high grade glioma (nct0231-3272)", Neuro-Oncology, 19(Suppl 6), pp.vi30~ (2017)